EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format

S C Saunderson, J C Halpin, G M Y Tan, P Shrivastava, A D McLellan

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03778-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von S C Saunderson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Otago, Dunedin, 9016, New Zealand. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Thromboplastin, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marsden Fund, Health Research Council of New Zealand, University of Otago.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of antibody-targeted therapy of solid cancers is limited by the lack of consistent tumour-associated antigen expression. However, tumour-associated antigens shared with non-malignant cells may still be targeted using conditionally activated-antibodies, or by chimeric antigen receptor (CAR) T cells or CAR NK cells activated either by the tumour microenvironment or following 'unlocking' via multiple antigen-recognition. In this study, we have focused on tissue factor (TF; CD142), a type I membrane protein present on a range of solid tumours as a basis for future development of conditionally-activated BiTE or CAR T cells. TF is frequently upregulated on multiple solid tumours providing a selective advantage for growth, immune evasion and metastasis, as well as contributing to the pathology of thrombosis via the extrinsic coagulation pathway.

Methods

Two well-characterised anti-TF monoclonal antibodies (mAb) were cloned into expression or transposon vectors to produce single chain (scFv) BiTE for assessment as CAR and CD28-CD3-based CAR or CD3-based BiTE. The affinities of both scFv formats for TF were determined by surface plasmon resonance. Jurkat cell line-based assays were used to confirm the activity of the BiTE or CAR constructs.

Results

The anti-TF mAb hATR-5 and TF8-5G9 mAb were shown to maintain their nanomolar affinities following conversion into a single chain (scFv) format and could be utilised as CD28-CD3-based CAR or CD3-based BiTE format.

Conclusion

Because of the broad expression of TF on a range of solid cancers, anti-TF antibody formats provide a useful addition for the development of conditionally activated biologics for antibody and cellular-based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenThromboplastinT-LymphocytesHumansImmunotherapy, AdoptiveSingle-Chain AntibodiesNeoplasmsJurkat Cells

Stichwörter der Autor:innen

Bi-specific T cell engagerChimeric antigen receptorSurface plasmon resonanceTissue factor

Substanzen

Receptors, Chimeric AntigenThromboplastinSingle-Chain Antibodies

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Otago, Dunedin, 9016, New Zealand.
  • The Children's Hospital Westmead, The Children's Hospital Westmead CRN Hawksbury Road and Hainsworth Street, Westmead, NSW, 2145, Australia.
  • Molecular and Clinical Cancer Medicine, The University of Liverpool, Crown St., Liverpool, UK.
  • Department of Microbiology and Immunology, University of Otago, Dunedin, 9016, New Zealand. alex.mclellan@otago.ac.nz.

Förderung

  • Marsden Fund
  • Health Research Council of New Zealand
  • University of Otago

Zitieren

APA

Saunderson, S. C., Halpin, J. C., Tan, G. M. Y., Shrivastava, P., & McLellan, A. D. (2024). Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03778-3

Vancouver

Saunderson SC, Halpin JC, Tan GMY, Shrivastava P, McLellan AD. Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03778-3

BibTeX
@article{Saunderson2024,
  author = {Saunderson, S C and Halpin, J C and Tan, G M Y and Shrivastava, P and McLellan, A D},
  title = {Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03778-3}
}
Kostenlos starten →